525 Rec'd PCT/PTO 20 UU I ZUUU

FORM P	TO-139 -98)	0 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER					
(RANSMITTAL LETTER TO THE UNITED STATES	41934/23838					
		DESIGNATED/ELECTED OFFICE (DO/EO/US)	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR					
	CONCERNING A FILING UNDER 35 U.S.C. 371 09/673785							
INTER		IONAL APPLICATION NO. INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED					
TITLE		PCT/GB99/01211 21.04.99	22.04.98					
		E FRAGMENTS OF MURINE EPIDERMAL GROWTH FACTOR	AS LAMININ RECEPTOR TARGETS					
		I(S) FOR DO/EO/US EEN'S UNIVERSITY OF BELFAST						
	QU.	DELLO CIVIT ENGILL OF BEELLOS						
Appli	cant h	nerewith submits to the United States Designated/Elected Office (DO/EO/US) the	e following items and other information:					
1.	×	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.						
2.		This is a SECOND or SUBSEQUENT submission of items concerning a filing	g under 35 U.S.C. 371.					
3.	×	This is an express request to begin national examination procedures (35 U.S.C.	371(f)) at any time rather than delay					
		examination until the expiration of the applicable time limit set in 35 U.S.C. 37	1(b) and PCT Articles 22 and 39(1).					
4.	×	A proper Demand for International Preliminary Examination was made by the	19th month from the earliest claimed priority date.					
5.	X	A copy of the International Application as filed (35 U.S.C. 371 (c) (2))						
		a. \(\text{\tinit}}\\ \text{\tex{\tex	ational Bureau).					
and Total		b. has been transmitted by the International Bureau.	oring Office (DO/HS)					
T 116: 7: 8: 7: 13	П	c. is not required, as the application was filed in the United States Received Attraction of the International Application into English (35 U.S.C. 371(a)(2))	· , ,					
9 .		A translation of the International Application into English (35 U.S.C. 371(c)(2)	<i>)).</i>					
	⊠ ⊠	A copy of the International Search Report (PCT/ISA/210).	10 (25 U.S.C. 271 (5)(2))					
	×	Amendments to the claims of the International Application under PCT Article 1 a. are transmitted herewith (required only if not transmitted by the International Application under PCT Article 1 a. b. construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the International Application under PCT Article 1 construction of the Internation under PCT Article	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1					
ri Ti		` . ,	iational Bureau).					
in		 b. have been transmitted by the International Bureau. c. have not been made; however, the time limit for making such amendments. 	cente has NOT avnivad					
ie.		 d. have not been made; however, the time limit for making such amender d. have not been made and will not be made. 	ients has 1401 expired.					
		A translation of the amendments to the claims under PCT Article 19 (35 U.S.C.	271(c)(3))					
9. 10. H.	⋈	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).	. 371(6)(3)).					
ij.	⊠ ⊠							
a1•9 ∰.		A copy of the International Preliminary Examination Report (PCT/IPEA/409). A translation of the annexes to the International Preliminary Examination Repo	art under PCT Article 36					
1 2 .		(35 U.S.C. 371 (c)(5)).	At tillides 1 O1 Article 30					
Ite	ems 1	3 to 20 below concern document(s) or information included:						
13.		An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
14.		An assignment document for recording. A separate cover sheet in compliance v	with 37 CFR 3.28 and 3.31 is included.					
15.		A FIRST preliminary amendment.						
16.		A SECOND or SUBSEQUENT preliminary amendment.						
17.		A substitute specification.						
18.		A change of power of attorney and/or address letter.						
19.	×	Certificate of Mailing by Express Mail						
20.		Other items or information:						

PCTUS1/REV03

422 Rec'a PCT/P10 2 0 OCT 2000

U.S. APPLICATION NO, (IE KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATI PCT/GB99/012	1	ATTORNEY'S DOCKET NUMBER 41934/23838	
	FC1/GB55/012.	<u> </u>		
21. The following fees are submitted:. BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) -	(5)) •		CALCULATION	S PTO USE ONLY
Neither international preliminary examination international search fee (37 CFR 1.445(a)(2) and International Search Report not prepared	n fee (37 CFR 1.482) nor paid to USPTO	\$1,000.00		
International preliminary examination fee (37 USPTO but Internation Search Report prepar	CFR 1.482) not paid to			
International preliminary examination fee (37) but international search fee (37 CFR 1.445(a)	CFR 1.482) not paid to USPTO (2)) paid to USPTO	\$710.00		
☐ International preliminary examination fee pai but all claims did not satisfy provisions of PC	d to USPTO (37 CFR 1.482) T Article 33(1)-(4)	\$690.00		
 International preliminary examination fee pai and all claims satisfied provisions of PCT Ar 	d to USPTO (37 CFR 1.482) ticle 33(1)-(4)	\$100.00		
ENTER APPROPRI	ATE BASIC FEE AMO	OUNT =	\$860.00	
Surcharge of \$130.00 for furnishing the oath or deck months from the earliest claimed priority date (37 C	aration later than \Box 20 FR 1.492 (e)).	0 🗆 30	\$0.00	
CLAIMS NUMBER FILED	NUMBER EXTRA	RATE		
Total claims 8 - 20 =	0	x \$18.00	\$0.00	
Independent claims 3 - 3 =	0	x \$80.00	\$0.00	
Multiple Dependent Claims (check if applicable).	A DOME CAT CHI AT	NONG.	\$270.00	
	ABOVE CALCULAT		\$1,130.00	
Reduction of 1/2 for filing by small entity, if applications also be filed (Note 37 CFR 1.9, 1.27, 1.28) (ch	ble. Verified Small Entity State leck if applicable).	ement	\$0.00	
	SUB	ΓOTAL =	\$1,130.00	
Processing fee of \$130.00 for furnishing the English months from the earliest claimed priority date (37 C	translation later than	0 🗆 30 +	\$0.00	
	TOTAL NATIONAL	LFEE =	\$1,130.00	
Fee for recording the enclosed assignment (37 CFR accompanied by an appropriate cover sheet (37 CFR	1,21(h)). The assignment must b	e	\$0.00	
a specification of the property of the specification of the specificatio	TOTAL FEES ENCL		\$1,130.00	
je sis	TOTALTEESENCE	OSED	Amount to be:	\$
And the state of t			refunded charged	\$
A check in the amount of	to cover the above fees is end	losed.	chargod	
Please charge my Deposit Account No.	20-0823 in the amount of	\$1,130.00	to cover the above	ve fees.
A duplicate copy of this sheet is enclosed.				
The Commissioner is hereby authorized to c	harge any fees which may be rec	quired, or credit as	ny overpayment	
to Deposit Account No. 20-0823	A duplicate copy of this sheet is	enclosed.		
NOTE: Where an appropriate time limit under 3' 1.137(a) or (b)) must be filed and granted to restor			on to revive (37 CFF	R
SEND ALL CORRESPONDENCE TO:	to the apprention to pending se			
PAUL A. LESKO		6 7		
THOMPSON COBURN LLP		SIGNATÜRE		
One Firstar Plaza St. Louis, Missouri 63101		PAUL A. LE	SKO	
Telephone: 314-552-6443		NAME		
Fax: 314-552-7443		45364		
1		REGISTRATIO	ON NUMBER	
		20 OCTOBE		
			<u> </u>	
[:	į.	DATE		

09/673785

WO 99/54356

PCT/GB99/01211 422 Rec'd PCT/PTO 2 0 OCT 2000

PEPTIDE FRAGMENTS OF MURINE EPIDERMAL GROWTH FACTOR AS LAMININ RECEPTOR TARGETS

1 2 This invention relates to the use of (synthetic and 3 modified) laminin receptor-targetted ligands for the 4 treatment of angiogenic diseases such as proliferative 5 retinopathies and metastatic cancer as well as for the 6 treatment of Candida spp. infections, or parastic 7 infestations such as leishmania and trichomonas 8 vaginalis. 9 10 Laminin antagonists (which are anti-angiogenic) can be 11 used to inhibit secondary tumour spread (by inhibiting 12 tumour cell attachment) and to prevent growth of 13 metastatic secondaries (by inhibiting 14 neovascularisation). These antagonists could also be 15 used to treat other angiogenic disorders (such as 16 diabetic retinopathy). 17 18 Laminin agonists (which promote angiogenesis) could be 19 used to treat retinopathy of prematurity, and could 20 also be used to promote wound healing (for example in 21 corneal epithelium). 22 23 Both the antagonists and the agonists would be expected 24 to inhibit parasite binding to tissue surfaces and 25 would thus prevent infection or infestation. 26 27 Angiogenic diseases are those disorders which are 28 directly caused by, or complicated by the inappropriate 29 growth of new blood vessels. The major angiogenic 30 diseases include the common metastatic solid tissue 31

PCT/GB99/01211 WO 99/54356 2

1 (cancers	(breast,	gastrointestinal,	lung,	prostatic,
-----	---------	----------	-------------------	-------	------------

- etc), diabetic retinopathy, neovascular glaucoma, 2
- rheumatoid arthritis and psoriasis. Angiogenesis is 3
- the rate-limiting step in the growth of secondary 4
- tumours; inhibition of their neovascularisation is 5
- known to stop their growth. 6

7

- In this field it is already known that the native 8
- ligand of the 67kDa laminin receptor (67LR) is 9
- encompassed by the linear sequence of amino acids 925-10
- 933 of the laminin β -1 (previously known as laminin B1 11
- or b1) chain (numbering refers to the mature murine 12
- laminin β -1). Synthetic laminin β -1₉₂₅₋₉₃₃ (single letter 13
- amino acid code: CDPGYIGSR-NH2) has been shown to 14
- inhibit tumour establishment in mice, by inhibiting 15
- attachment of tumour cells to basement membranes. 16
- has also been demonstrated that laminin β -1₉₂₅₋₉₃₃ 17
- inhibits angiogenesis in the chick. 18

19

- However, synthetic laminin-derived peptide (laminin 20
- β -1₉₂₅₋₉₃₃) stimulates angiogenic events in mammalian 21
- cells (in which it acts as a pure 67LR agonist), making 22
- it useless as the basis of a human therapy. 23

24

- It is one object of the present invention to provide a 25
- medicament to treat angiogenic diseases. 26

27

- The present invention provides a peptide factor derived 28
- from murine epidermal growth factor (EGF) peptide for 29
- use in the preparation of a medicament for the 30
- treatment of angiogenic diseases. 31

32

- The mechanism by which EGF derived peptides inhibit new 33
- blood vessel formation is through their antagonism of 34
- the high affinity 67 kDa laminin receptor (67LR) found 35
- on endothelial cells. 36

PCT/GB99/01211 WO 99/54356

	3
1	The peptides have the additional effect of inhibiting
2	tumour cell attachment to basement membranes, and may
3	be used to prevent solid cancer spread in cases where
4	cancer cells have been identified circulating in the
5	blood.
6	
7	Modified peptides may be protected from proteolytic
8	degradation by substitution of key residues with
9	unnatural amino acid analogues at susceptible bonds,
10	such as tyrosine analogues (at position 5) and arginine
11	analogues (at position 9). The peptides may be capped
12	at N - and C -termini (with acetyl and amide groups
13	respectively) and at the thiol groups of the cysteines
14	(with acetamido methyl groups).
15	
16	Typically the peptide is an antagonist of the 67kDa
17	Laminin Receptor (67LR).
18	
19	The peptide factor is based on amino acid residues 33
20	to 42 of murine epidermal growth factor (mEGF).
21	
22	The amino acid sequence of mEGF- (33-42) is CVIGYSGDRC.
23	
24	Preferably the sequence of peptide factor is modified
25	from the natural sequence to protect the peptides from
26	protease attack.
27	
28	Preferred substitutions include the use of tyrosine
29	analogues at position 5 and arginine analogues at
30	position 9.
31	
32	Preferably the peptide factor is capped at the N

terminal with an acetyl group. 33

34

Preferably the peptide factor is capped at the C 35 terminal with an amide group. 36

WO 99/54356 PCT/GB99/01211

4

1 Preferably the thiol groups of cysteines are capped 2 with acetamido methyl groups.

3 4

In one embodiment the synthetic peptide has the sequence

5 6 7

Acetyl-C-[S-Acm]-VIGYSGDR-C-[S-Acm]NH2

8

A preferred tyrosine analogue is Tic-OH.

10 11

A preferred arginine analogue is Citrulline.

12

13 The structure of Citrulline and other potential 14 arginine analogues are shown below.

15 16

Citrulline and analogues

17 18

19

citrulline

-HN CO-
$$\begin{cases} n = 1,2 \\ 1 \end{cases}$$

cysteine-derived analogues

(prepared by reaction of cysteine with $Br-(CH_2)_n$ -CONH₂)

29 30

36


26

27

28

31 32 33 34 35

thiono-citrulline



homo-glutamine

{prepared by reaction of ornithine with ammonium isothiocyanate}

PCT/GB99/01211 WO 99/54356

5

Preferably the peptide is truncated to a shorter 1

peptide without losing its antagonistic character. 2

3 The invention further provides a peptide agonist. 4

5

The agonist may be the native sequence (single letter 6

amino acid code:CDPGYIGSR-NH2) or may have the tyrosine 7

substituted by any of a variety of tyrosine analogues 8

such as the comformationally restricted Tic-OH or 9

2',6'-dimethyl-beta-methyl-tyrosines, 2-0-methyl and 2-10

O-ethyl-tyrosine and the like. 11

12

The agonist may be useful in healing endothelial cell 13

wounding. 14

15

For example, corneal endothelial cells can be damaged 16

during cataract operations and this damage does not 17

self-repair because these endothelial cells do not 18

divide. Healing can only be effected by cell migration 19

and spreading, and this may be promoted by the agonist. 20

21

In order to explore possible conformations for the 22

parent mEGF33.42 peptide, it was modelled using molecular 23

dynamics. Based on these conformations a strategy has 24

been predicted to provide proteolytic protection by 25

being able to identify residues that are important to 26

the maintenance of a three-dimensional conformation 27

essential for 67LR recognition.

28 29

The following is a description of some examples of 30

modifications and uses of the invention. 31

32

On the basis of the modelled structures, it was 33 1.

found that the arginine residue participated in H-34

bonding, and speculated that this charge may not 35

be important. A peptide was synthesised based on 36

36

PCT/GB99/01211 WO 99/54356 6 $mEGF_{33-42}$, in which the arginine residue at position 1 41 was replaced by citrulline (an uncharged 2 arginine mimetic with similar H-bonding 3 potential). This peptide provided to act as a 4 more potent 67LR antagonist and was found to be 5 resistant to trypsin degradation. 6 7 Double substitution of tyrosine, with Tic-OH and 2. 8 arginine41 with citrulline, to produce a mEGF33-42-9 derived peptide resistant to both chymotrypsin-10 like and trypsin-like proteases. 11 12 Replacement of susceptible peptide bonds in mEGF₃₃. 13 3. with protease-resistant peptide bond isosteres 14 (such as thionopeptide or methylene amino bonds). 15 16 Conformationally restricted analogues may give 17 4. improved potency due to the essential 3-18 dimensional conformation being stabilised. 19 example, it should be possible to increase the 20 rigidity of the molecule by replacing each of the 21 central glycine residues in turn by α, α -dialkyl 22 substituted amino acids such as α -amino isobutyric 23 acid (AIB) or aminocyclopropane carboxylic acid 24 (ACPCA). Alternatively, the helical turn (which 25 we have identified as essential) could be 26 stabilised by bridging with suitable intra-chain 27 linkers, such as a disulphide bond between N- and 28 C-terminal [D] or [L]-cysteines. 29 30 EXAMPLE 1 31 32 The invention is demonstrated with reference to 33 the following figures wherein. 34 35

Figure 1a depicts a flat mount retina showing the

WO 99/54356 PCT/GB99/01211

7

effects of ROP and Figure 1b depicts a retina from laminin-agonist treated mouse showing recanalisation of vessels.

4

Treatment of Retinopathy of Prematurity (ROP)

6 7 8

9

10

11

12

13

14

15

16

17

18 19

20

21

22

23

2425

Severely premature babies are at risk of developing retinopathies due to their being exposed to high oxygen levels post-partum. This life-saving intervention compensates for poor lung development but has the unfortunate side-effect of causing unnaturally hyperoxic conditions in the The direct effect of this is to remove the normal hypoxic cues for endothelial migration, resulting in inhibition of capillary growth and vaso-obliteration. When these babies are returned to room air, hypoxic stimuli are restored and retinal angiogenesis is again induced. However, the newly induced angiogenesis is chaotic and uncontrolled, often resulting in abnormal penetration of vessels into the vitreous (see Figure 1a, below). It is the uncontrolled growth of these blood vessels that ultimately leads to loss of visual activity.

26

27

28

29

30

31 32

33

34

35 36 It has now been shown that laminin agonist treatment can reverse the effects of both hyperoxic induced vaso-ablation as well as norm-oxic-induced angiogenesis in a murine model of retinopathy of prematurity (ROP). In this model, development of ROP can be prevented by treatment of neonates with daily injections (intraperitoneal) of $10\mu g$ of synthetic laminin β - $1_{925-933}$ (also referred to as laminin $B1_{925-933}$, single letter amino acid code:CDPGYIGSR-NH₂). See Figure

WO 99/54356

PCT/GB99/01211

8 1b in comparison with 1a. Treatment with laminin 1 agonist (Figure 1b) prevents the uncontrolled 2 3 angiogenic response of ROP (Figure 1a) and promotes re-canalisation of areas of vaso-4 obliteration. 5 6 7 The invention is demonstrated with reference to the following figures wherein Figure 1a depicts a 8 9 flat mount retina showing the effects of ROP 10 Figure 1b depicts a retina from laminin-agonist 11 treated mouse showing re-canalisation of vessels. 12 13 Murine model of proliferative retinopathy 14 15 16 Litters of 7 day old C57-BL/6J mice, together with their nursing dams, are exposed to 80% oxygen in 17 an incubator maintained at 23°C and with a gas 18 exchange of 1.5L/min for 5 days according to the 19 20 protocol described by Stitt et al. (1998). On postnatal day 12 (P12) the animals are returned to 21 room air and sacrificed at various times post-22 hyperoxia. Animals are treated with daily i.p. 23 24 injections of either laminin agonists (10µg per head per day) or vehicle control. Groups of room 25 26 air controls are maintained in parallel with 27 hyperoxia-exposed animals. Home Office project 28 and personal licenses are held for this work. All animals are housed and maintained in accordance 29 30 with the ARVO regulations for animal care in 31 research. 32 Animals are sacrificed at pre-determined key 33 34 stages in the vaso-obliteration (P7-P12), 35 ischaemia (P12 onwards) and vaso-proliferative 36 responses (P12-21). At sacrifice, terminally

WO 99/54356 PCT/GB99/01211 9

anaesthetised animals have a single eye enucleated 1 and the retina removed to be snap-frozen for later 2 RNA-extraction (see below). The fellow eye is 3 either perfused with fluorescein dextran or 4 enucleated and fixed in 4% paraformaldehyde for 5 6 histology, immunohistochemistry and in situ 7 hybridisation.

8 9

ALTERNATIVE USES

10 11

Treatment of corneal wounds 1.

12 13

14

15

16

17 18

19

20

21

22

23

24

25

27

28

29

30

31

32

33

34

35

36

The cornea is a delicate transparent structure. Being avascular, corneal wound healing depends upon local self-renewal of the corneal epithelium. This, in turn, depends upon the presence of a mitogenically functional stem cell population ('limbal cells'), which produce replacement cells that migrate and desquamate at the denuded area. Damage to these underlying stem cell populations causes inappropriate re-epithelialization by conjunctival cells followed by matrix deposition and scar formation. The damaging agent may be corrosive chemical or heat burns, erosion by contact lenses, Stevens Johnson disease.

26

It is known that transplantation of limbal cell autografts from the unaffected eye can restore a stable healing of the corneal epithelium (Kenyon et al., 1996). It has been proposed that harvesting small samples of limbal stem cells, followed by serial culture in vitro would provide greater chance of success (particularly when both eyes are affected) De Luca, et al., 1997). However, with both protocols, correct uptake and controlled migration of these grafted cells into

PCT/GB99/01211

A TON OF AND

with this this this

*

THE REAL PORTS (FOR

WO 99/54356

10	
----	--

the corne	al epithelium	has not	been	optimised.
-----------	---------------	---------	------	------------

2 3

4

5

б

7

We propose that laminin agonists could be used to stimulate the migratory response of the cells prior to grafting, or alternatively topical application of laminin agonists to the wound site could be used to direct migration of the grafted cells to the correct (denuded) area of the cornea.

8 9 10

11

12

13

14

15

Some microbial pathogens such as Candida albicans, 2. express 67LR and use this as a means of attaching to human basement membranes. It is conceivable that such infections could be abolished by treatment with mEGF33-42-derived peptides, which would prevent the microbes from adhering to the host.

16 17 18

19

21

EXAMPLE 2

20

Peptide Study

The purpose of the investigation was to determine the 22 23 24

molecular target of mEGF(33-42) and to identify the amino acids that are essential for receptor recognition. In addition, the key residues which confer laminin antagonism on $mEGF_{(33-42)}$ were examined.

26 27 28

29

30

31

32

33

34

25

Two lead compounds were investigated; synthetic laminin β -1 sequence CDPGYIGSR-NH₂ and mEGF₍₃₃₋₄₂₎ sequence AcC(Acm) - VIGYSGDRC - (Acm) - NH₂. Bearing in mind the pure antagonism of the murine EGF peptide, the aims of this study were to identify the key residues responsible for these contrasting activities using alanine scanning, in the context of developing anti-angiogenic drugs for retinopathy treatment.

35 36

34

35

36

PCT/GB99/01211 WO 99/54356

	11
1	In addition, using residue exchange between the two
2	peptides and molecular modelling to predict three-
3	dimensional structure, we wished to further investigate
4	the role of individual $mEGF_{(33-42)}$ residues in laminin
5	antagonism. A logical series of peptides was
6	synthesised and screened for receptor interaction, cell
7	adhesion and motility properties (Table la and 1b).
8	
9	MATERIALS AND METHODS
10	
11	Peptide synthesis
12	
13	Peptide sequences based on and mEGF(33-42) were
14	synthesised on a model 432A peptide synthesizer
15	(Applied Biosystems, Warrington, UK), using standard
16	solid-phase Fmoc procedure (Fields 1990). Synthesis of
17	the peptides required successive additions of
18	derivatized amino acids to form a linear product.
19	
20	Peptides were purified after synthesis using reverse
21	phase HPLC and purity confirmed by automated amino acid
22	analysis and electrospray mass spectrometry. All
23	peptide sequences were stored in the presence of
24	desiccant at -20°C until required for biological assay.
25	
26	Laminin receptor antibody production
27	
28	a. Preparation of MAPs
29	
30	The peptide sequence (PTEDWSAQPATEDWSAAPTA),
31	corresponding to the COOH-terminal end of the human
32	laminin receptor, was used as the antigen template.
33	Derivation of the peptide, based on a CN-Br cleavage

fragment of the cDNA sequence encoding human laminin

receptor, has been described elsewhere (Wewer et al

1986). The antigen was synthesised as an octomeric

PCT/GB99/01211 WO 99/54356

12

peptide derivative (MAPs) using automated Fmoc 1

procedure (Tam 1988). 2

3 4

Table 1a: Peptide substitution 5

mEGF ₍₃₃₋	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ser	Gly	Asp	Arg	ACM Cys-NH ₂
I	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ile	Gly	Asp	Arg	ACM Cys-NH2
II .	acetyl	ACM Cys	Val	lle	Gly	Tyr	Ser	Gly	Ser	Arg	ACM Cys-NH ₂
Ш	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ile	Gly	Ser	Arg	ACM Cys-NH ₂
IV	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ser	Gly	Asp	Cit	ACM Cys-NH ₂
V	acetyl	ACM Cys	Val	Ile	Gly	OH Tic	Ser	Gly	Asp	Arg	ACM Cys-NH ₂

Table 1b: Peptide substitution (alanine scanning)

mEGF ₍₃₃₋ 42)	acetyl	ACM Cys	Val	Ile	Gly	Туг	Ser	Gly	Asp	Arg	ACM Cys- NH ₂
VI	acetyl	ACM Cys	Vai	Ala	Gly	Тут	Ser	Gly	Asp	Arg	ACM Cys- NH ₂
VII	acetyl	ACM Cys	Ala	Ile	Gly	Tyr	Ser	Gly	Asp	Arg	ACM Cys- NH ₂
VIII	acetyl	Ala	Val	Ile	Gly	Tyr	Ser	Gly	Asp	Arg	ACM Cys- NH ₂
ıx	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ser	Gly	Asp	Arg	Ala- NH ₂
Х	acetyl	ACM Cys	Val	Ile	Gly	Tyr	Ala	Gly	Asp	Arg	ACM Cys- NH2

PCT/GB99/01211 WO 99/54356

13

b.	Immun	isation	sche	du.	Le
----	-------	---------	------	-----	----

1 2

A pre-immune test bleed (5ml) was obtained from the 3

- marginal ear vein of a male New Zealand White rabbit 4
- (3.2 kg). The bleed was allowed to clot for 2 h at room 5
- temperature after which its edge was detached from the 6
- wall of the collection vessel. The clot was then 7
- allowed to contract overnight at 4°C. Serum was then 8
- removed and the residual material pelleted out by 9
- centrifugation (10 min at 2,500 g). Extracted serum 10
- (3.5 ml) was then frozen at -20°C until required. 11

12

- Immunogen was prepared by the emulsion of MAPs (0.5 g 13
- antiqen in 0.5 ml PBS) in an equivalent volume of 14
- adjuvant (Alum Imject; Pierce, Chester, UK). The 15
- animals immune system was primed by introducing 16
- immunogen (50 μ g) through subcutaneous injection at 17
- different sites on the animals back. The rabbit was 18
- boosted by both subcutaneous and intramuscular 19
- injection, 21 days after priming, using an increased 20
- dose of immunogen (800 μg). Subsequent boosts were 21
- performed by intramuscular injection after a further 14 22
- days (800 μg immunogen), and thereafter at 21 day 23
- intervals. Test bleeds were taken 2 days after each 24
- boost and the serum extracted as described above. The 25
- animal was boosted and bled a total of three times. 26

27

c. Enzyme-linked immunoabsorbent assay

28 29

- ELISA was used to determine the specificity of the 30
- antibody prepared against the synthetic MAPs peptide 31
- and to determine the efficacy of binding with respect 32
- to that of the linear precursor. 33

34

Peptides were dissolved in distilled water and diluted 35

WO 99/54356 PCT/GB99/01211

14

to 10 μ g/ml in coating buffer. Aliquots (100 μ l) of 1 either linear or MAPs peptide were then added to the 2 wells of microtitre plates (Microtest III; Becton 3 Dickinson Ltd., Oxford, UK) and incubated overnight at 4 37°C. The wells were then rinsed with 100 μ l wash 5 buffer and air dried. Excess adsorption sites were 6 blocked (1 h incubation at 22°C) by the addition of 10% 7 casein in PBS (0.1 ml/well). Subsequent to the removal 8 of casein solution by aspiration, wells were again 9 rinsed with wash buffer and air dried. 10

11 12

13

14

15

16

17

Antisera or pre-immune sera were then serially diluted in PBS and 100 μ l of each incubated in peptide coated wells for 1 h at 37°C. After rinsing (0.1 ml wash buffer), 100 μ l per well of 5 μ g/ml secondary antibody (horse-radish peroxidase-conjugated goat anti-rabbit IgG; Amersham International, Aylesbury, UK) was added to each well and the plates incubated at 37°C for 1 h.

18 19 20

21

22

23

24

25

Wells were again rinsed with wash buffer and 0.1 ml substrate solution (TMB peroxidase) added to each. The plate was then incubated at 22°C for 30 min and the colour reaction stopped by the addition of 0.5M $\rm H_2SO_4$ (0.1 ml/well). Absorbence was measured at 450 nm on a Titertek Multiscan plate reader.

26

d. Purification of IgG fraction

27 28

Anti-laminin receptor antiserum was purified using immobilised protein G-sepharose columns (Pharmacia Biotech, Uppasla, Sweden). The columns were equilibrated with 20 ml sodium phosphate buffer (pH 7.0). Antiserum was diluted 1:4 in the same buffer and a 1 ml aliquot loaded onto the column (flow rate 150 ml/h, fraction size 2.5 ml). After exclusion of the

PCT/GB99/01211 WO 99/54356

15

unbound fraction, as determined by absorbence at 280nm, 1 the IgG component of the antiserum was eluted with 0.1M 2

glycine-HCl (pH 2.7), into tubes containing 0.1 ml Tris 3

(1M), pH 9.0. The eluted IgG fractions were bulked and 4

stored at -20°C until required. 5

6 7

Maintenance of cell cultures

8

- Cancer and endothelial cells were maintained in either 9 DMEM (T47-D) or RPMI (SK HEP-1) media, supplemented 10
- with 10% FCS, 100 IU/ml penicillin and 100 μ g/ml 11
- streptomycin. Cells were incubated at 37°C in a 12
- humidified atmosphere of 95% air: 5% CO2 and media 13
- refreshed as required. Cultures (at 80-85% confluence) 14
- were routinely passed on removal from monolayer by the 15
- action of trypsin (0.25%) and EDTA (0.02%) in CFS. 16

17

- The viability of cell populations following 18
- trypsinisation was determined by the trypan blue vital 19
- dye exclusion test. Populations confirmed as being in 20
- excess of 95% viable were used in all studies. 21

22

- Media were screened for possible bacterial or fungal 23
- contamination by incubating 1ml aliquots with both 24
- nutrient and Saboraud dextrose broths (Oxoid Ltd., 25
- Basingstoke, UK). Cell populations were routinely 26
- monitored for sub-clinical infections by periodically 27
- culturing in the absence of antibiotics. 28

29

- Both cell lines and media were examined for the 30
- presence of contaminating Mycoplasma spp. by the method 31
- of Chen (1977). 32
- Determination of cell numbers 33

34

Single cell suspensions were quantified using an 35

PCT/GB99/01211 WO 99/54356

16

1	automated	counter	(Coulter	Electronics,	Harpenden,	UK).

- A 1 ml aliquot of cell suspension was diluted 1 in 20 2
- in Isoton and 0.5 ml samples counted. The mean of 5 3
- counts was taken and the total number of cells 4
- determined. Estimates of cell number were confirmed by 5
- counting in a haemocytometer. 6

7

- For microtitre end-point assays, cell numbers were 8
- estimated from the crystal violet staining index of the 9
- cell line (Kanamaru and Yoshida 1989). Briefly, after 10
- removal of media from the assay system cells were fixed 11
- with formaldehyde (10% in PBS), and washed with 12
- distilled H_2O . Aliquots (100 μ l) of crystal violet 13
- solution (0.1% in distilled H2O) were added to each well 14
- and the plates allowed to stand for 30 min. Excess 15
- stain was removed by rinsing with distilled H_2O (3 x 100 16
- μ l). The wells were then air-dried and the remaining 17
- crystal violet extracted with 100 μ l acidified 18
- methanol. Absorbance at 620 nm was determined using a 19
- Titertek Multiscan spectrophotometer. 20

21 22

Proliferation assays

23

- The effects of synthetic peptides and growth factors on 24 the growth of breast cancer and endothelial cells were 25
- determined as detailed. 26

27

- Exponentially growing cells were harvested by 28
- trypsinisation, as previously described. After rinsing 29
- and resuspending in the relevant culture media 30
- (containing 10% FCS), the cells (100 μ l aliquots) were 31
- dispensed into 96-well microtitre plates at a 32
- population density of 2 x 104 cells/well (6 wells per 33
- experimental condition). Cells were the incubated for 34
- 24 h at 37°C after which the media was removed and the 35

PCT/GB99/01211 WO 99/54356

17

wells rinsed with CFS (3 x 100 μ l), to rid the plates 1 of cells in suspension. Media was then replaced with 2 that containing the relevant controls or treatment 3 supplements as detailed in individual experiments. 4

5 6

Cell numbers were evaluated spectrophotometrically at 620 nm, over the period of assay, after fixing with 10% formaldehyde and staining with crystal violet.

8 9

7

Proliferative responses were analysed using the 10 Wilcoxan Rank test and significant differences at the p11 < 0.05 level, defined. Results of all growth studies 12 were confirmed in at least 3 individual experiments. 13

14 15

Laminin attachment assay

16 17

18

19

20

21

22

23

24

Non-tissue culture grade 96-well plates, coated with 2.5 μg murine laminin in 50 μl CFS per well, were airdried overnight at room temperature. Preliminary experiments indicated that cell attachment was concentration dependent; maximal binding occurred at a laminin coating of 2.5 μ g/well. After rinsing with CFS (100 μ l), the plastic was saturated with casein (0.2% in CFS). Plates were incubated at room temperature for 45 min then washed extensively with CFS (3 x 100 μ 1).

25 26 27

28

29

30

After removal of culture media, cells were detached from monolayers by the action of EGTA (0.02% in CFS) at 37°C. The cells were then centrifuged at 800 g for 2 min and the pellet resuspended in DMEM (T-47D) or RPMI (SK HEP-1).

31 32

Cells, at a population density of 10° cells/ml, were 33 then aliquoted (1 ml) into microfuge tubes containing 34 the individual peptide sequences and incubated for 1 h 35

PCT/GB99/01211 WO 99/54356 18

at 37°C. The cells (100 μ l aliquots) were then added to 1

- the pre-coated multi-well plates and incubated for a 2
- further 60 min. Incubation media were removed and the 3
- wells washed with CFS (3 x 100 μ l) to rid the plates of 4
- non-adherent cells. 5

6

- Attached cell numbers were evaluated 7
- spectrophotometrically at 620 nm after fixing with 10% 8
- formaldehyde and staining with crystal violet. 9

10 11

Attachment to mEGF (33-42)

12

- That mEGF₍₃₃₋₄₂₎ bound to the 67kDa laminin receptor was 13
- demonstrated using a biotinylated derivative of the 14
- peptide (Acetyl-C-[S-Acm]-VIGYSGDR-C-[S-Acm]-K-[N-15
- biotin]-amide) and a modification of the above laminin 16
- attachment assay. 17

18

- Briefly, 96-well plates were coated with 100 μ l/well 19
- streptavidin (5 μ g/ml in carbonate buffer pH 9.6) and 20
- following an overnight incubation at 37°C, wells were 21
- washed with CFS (3 x 100 μ l) and the plastic blocked 22
- with casein (0.2% in CFS). The plates were then 23
- incubated at room temperature for 45 min and washed 24
- with CFS as previously detailed. Biotinylated mEGF(33-42) 25
- in CFS was then aliquoted into the wells (0.1 ml of 100 26
- μM) and the plates incubated for 3 h at 37°C. 27

28

- After a further block with 0.2% casein, the wells were 29
- washed with CFS (3 x 100 μ l aliquots). Plates were kept 30
- at 4°C and used within 2 h. 31

32

- Cells were prepared as above and pre-incubated for 1 h 33
- at 37°C with serial dilutions of anti-laminin receptor 34
- polyclonal (see below) or anti-EGF (R1) receptor 35

PCT/GB99/01211 WO 99/54356

19

monoclonal antibodies. Subsequent procedures were as 1

detailed for the laminin attachment assay. 2

3 4

Laminin receptor binding determinations

5 6

a. Radiolabelling of laminin

7

125 I-laminin was prepared using 125 I-labelled sodium 8

iodide (Amersham, UK) and immobilised chloramine-T 9

(Iodobeads; Pierce, Illinois). Prior to use, the beads 10

were washed with 500 μ l phosphate buffer (pH 6.5) to 11

remove excess reagent from the support. These were then 12

allowed to air dry and individual beads added to a 13

solution of carrier free Na¹²⁵I, diluted with iodination 14

buffer (phosphate buffer pH 7.4). The beads were 15

allowed to equilibrate for 5 min. 16

17

20

Laminin (10 μ g in 10 μ l) was then diluted into the 18

iodination buffer and the system incubated at 20°C for 19

15 min. The solution was then removed from the reaction

vessel and excess Na125I and unincorporated 125I2 21

separated from the iodinated protein by gel filtration 22

on a GF-5 exclusion column (Pierce, Illinois). 23

Iodinated laminin fractions were recovered at a 24

specific activity of approximately 1.2 mCi/mg protein 25

(864 Ci/mmol). 26

27

b. Competition binding estimation

28 29

Near confluent cultures of T47-D or SK HEP-1 cells were 30

removed from monolayer with 0.02% EGTA and passed 31

through a G-25 syringe needle to produce single cell 32

suspensions. Aliquots of each cell type (106 cells/ml) 33

were dispensed into separate Ependorf tubes (1 ml each) 34

and pelleted. The cells were then resuspended in 1 ml 35

PCT/GB99/01211 WO 99/54356

20

ice-cold RPMI (SK HEP-1) or DMEM (T47-D) containing 1 0.1% BSA and either laminin or synthetic peptide at the 2 concentrations indicated. Iodinated laminin was then 3 added to each cell suspension to give a final 125I-4 laminin concentration of 0.1 nM (approximately 50,000 5 cpm). These mixtures were incubated overnight at 4°C.

7 8

6

9

10

11

12

13

The tubes were then microfuged at 10,000 g and the supernatant removed. After washing the pellet with 500 μ l CFS, the remaining radioactivity was determined using a gamma radiation counter. Non-specific binding was determined by incubating cells with a 1000-fold molar excess of unlabelled laminin. All estimations were carried out in triplicate.

14 15 16

17

18

19

20

IC₅₀ (concentration of unlabelled peptide required to produce 50% inhibition of radioligand binding) and EC50 (effective concentration for 50% inhibition of cell attachment) values were calculated using the Grafit curve-fitting programme (Erithacus Software, London, UK).

21 22

Migration assays

23 24 25

26

27

28

29

30

31

The method used was basically as described by Albrecht-Buehler (1977). Briefly, coverslips (22 x 22 mm) were treated in 5% detergent (7X; ICN Biomedicals) and washed in alcohol to remove grease. After drying, they were immersed in gelatin solution (Sigma, 300 Bloom; 0.5 g in 300 ml distilled H₂O) for 10 min. The coverslips were then dried by placing in a 70°C oven for 45 min.

32 33

Colloidal gold suspension was prepared by adding 11 ml 34 distilled H2O and 6 ml Na2CO3 (36.5 mM) to 1.8 ml AuHCl4 35

PCT/GB99/01211 WO 99/54356

21

(14.5 mM). The mixture was heated to 95°C at which 1

- point 1.8 ml of freshly prepared 0.1% formaldehyde 2
- solution was added; the temperature was maintained at 3
- 95°C. A suspension of colloidal gold was formed which 4
- was brown to absorbed light and blue to transmitted 5
- light. 6

7

- The gold suspension, was then added to petri dishes 8
- containing individual coverslips and the plates 9
- incubated at 37°C for 45 min. After washing with CFS (3 10
- x 4 ml) to remove unattached gold particles, the 11
- coverslips were transferred to 6-well cluster dishes 12
- and UV sterilised. 13

14

- Endothelial cells (SK HEP-1 and BRCE) in culture media 15
- (0.3 ml) were seeded onto the coverslips at an 16
- approximate density of 5 x 103 cells per well. The cells 17
- were allowed to plate down for 2 h at 37°C after which 18
- the treatments were added. Assay systems were 19
- maintained for a further 18 h after which the cells 20
- were fixed using 3% gluteraldehyde in cacodylate buffer 21
- 22 (pH 7.2).

23

- The assays were examined using a Leica DM1RB phase 24
- contrast microscope and Q500MC image analysis system 25
- incorporating a JVC TK-1280E colour camera (Leica, 26
- Milton Keynes, UK). The track images of at least 30 27
- cells were video-captured and the area (representing 28
- migration response) determined for each. Statistical 29
- analysis of these areas was then carried out using 30
- Macintosh Instat software to perform both Kruskal-31
- Wallis analysis of variance and Mann-Whitney U-tests in 32
- order to compare the treatment groups with controls. 33

34

35 RESULTS

PCT/GB99/01211 WO 99/54356

22

proliferative response 1

2

- All peptides were examined for their ability to 3
- influence the growth of T47-D and SK-Hep 1 cell lines. 4
- At concentrations of peptide up to $100\mu M$, no 5
- significant effects were observed in either cell line. 6

7

Mechanism of action

8 9

- It had shown previously that mEGF(33-42) could inhibit the 10
- EGF-stimulated angiogenic response in the early chick 11
- as well as blocking the basal and EGF-stimulated 12
- motility of primary and established endothelial cells. 13

14

- During the present study it is shown that mEGF(33-42) also 15
- inhibits the angiogenic effects of laminin (Nelson et 16
- al 1995). Furthermore, it is demonstrated that the 17
- anti-angiogenic effects of mEGF(33-42) are mediated solely 18
- through the high affinity 67 kDa laminin receptor (67-19
- LR) and not through the EGF receptor. 20

21

- The study also confirms that $mEGF_{(33-42)}$, Lam. β -1 $_{(925-933)}$ and 22
- laminin are equipotent in 125I-laminin displacement 23
- receptor assays, and that both of the small peptidal 24
- ligands have similar potencies in specific laminin cell 25
- 26 attachment assays.

27

- In addition, it is shown that the commonly used chick 28
- angiogenesis models are not appropriate to the study of 29
- laminin mediated human angiogenesis: although it is 30
- confirmed that Lam. β -1₍₉₂₅₋₉₃₃₎ acts as a partial laminin 31
- antagonist in chick, it was found to be a pure agonist 32
- in mammalian cell lines. This is a highly significant 33
- point given that pharmaceutical companies (such as 34
- Angiotech, Vancouver, BC) are using the chick CAM assay 35

PCT/GB99/01211 WO 99/54356 23

as the sole screening method for the discovery of anti-1

angiogenic lead compounds. This may be inappropriate 2

for use in human disease. 3

4

This study is the first to show that the YIGSR-receptor 5

is, in fact, the 67 kda high affinity laminin receptor 6

(67-LR). In collaboration with Professor Archer's team 7

at the Department of Ophthalmology, Royal Victoria 8

Hospital, Belfast, it has been determined that the 67-9

LR is preferentially expressed in new vessels during 10

oxygen-induced retinopathy in neonatal mice. 11

12 13

Peptide antagonist development

14

The N-terminus of Lam. β -1₍₉₂₅₋₉₃₃₎ is not necessary for 15

receptor recognition and the agonist activity of YIGSR 16

peptide (Ostheimer et al 1992, Kawasaki et al 1994). 17

18 19

However, alanine scanning of the starting peptide

 $(mEGF_{(33-42)})$ indicated that residues at positions 1, 2, 20

3, and 6 (peptidesVI, VII, VIII and X respectively), 21

are essential for receptor mediated activities as 22

determined by 125I-laminin displacement and cell 23

attachment to laminin through the 67-LR. Substitution 24

of these individual residues by alanine leads to a 25

dramatic decrease in receptor affinity observed as an 26

increased IC_{50} (Table 2) and a parallel decrease in 27

their ability to block adhesion to laminin (increased 28

 EC_{50} ; Table 2). Characterisation of these analogues with 29

regard to effects on motility, largely confirmed these 30

findings although there was one exception; peptide 31

VIII. Results from the migration assay identified this 32

sequence (alanine for cysteine (P1)) as being a weak 33

laminin agonist despite there being a much reduced 34

response in the other two assays. It is suggested that 35

1997).

PCT/GB99/01211 WO 99/54356

24

this peptide may influence laminin receptor mediated 1 migration through an alternative mechanism (Scott 2

3 4

Substitution at P10 (alanine for cysteine (peptide X) 5 retains both receptor binding and adhesion displacing 6

activities but has the effect of changing the 7

antagonistic parent into an agonist analogue. This 8

reflects the response the agonism of Lam. β -1(925-933), 9

which also lacks the C-terminal cysteine, and suggests 10

that this cysteine is not essential for receptor 11

recognition, but is required for antagonism of mEGF(33. 12

13 42} 1

14

Studies have reported that the positive charge offered 15 by arginine (P9) is essential for the biological 16 activity of Lam. β -1₍₉₂₅₋₉₃₃₎ (McKelvey et al 1991, Kawasaki 17 et al 1994). Glutamate substitution for arginine 18 generates a negative charge at this position with 19 corresponding loss of biological activities (Kawasaki 20

21 22

23

24

25

26

27

28

29

30

31

32

et al 1994).

However, the substitution of arginine (P9) with positively-charged lysine (McKelvey et al 1991) also results in complete loss of ligand binding and biological activities, suggesting that the mere presence of a positive charge at this position is, in itself, insufficient for receptor recognition. This modelling studies suggest that H-bonding of the guanidino group of the arginyl residue to the aromatic sidechain of the tyrosyl residue (P5) in the consensus sequence GYXGXR presents an acceptable motif for 67-LR activation by both mEGF₍₃₃₋₄₂₎ and Lam. β -1₍₉₂₅₋₉₃₃₎.

33 34

Substitution of tyrosine (P5) with a conformationally 35

PCT/GB99/01211 WO 99/54356

25 restricted mimetic (tetrahydroisoquinoline-3-carboxylic 1 acid; Tic-OH) in peptide V converted the antagonist 2 $\mathtt{mEGF}_{(33-42)}$ into an agonist. This residue substitution 3 generates a predicted conformation unlikely to be able 4 to form H-bonds. Although both receptor binding and 5 adhesion responses were retained in this peptide the 6 loss of antagonism would suggest that H-bonding between 7 tyrosine (P5) and the arginine (P9) is important for 8 these antagonist activities. 9 10 Modelling studies suggested that citrulline (an 11 uncharged arginine mimetic) would also be capable of 12 forming this H-bonded motif. 13 14 It was found that replacement of arginine (P9) with 15 citrulline (peptide IV) increased both receptor binding 16 and inhibition of attachment to laminin substrata 17 whilst retaining antagonist migratory response (Table 18 2), reinforcing the observation that it is not the 19 positive charge that is required rather than an active 20 conformation generated by hydrogen bonding. These 21 findings thus identify H-bonding between P5 and P9 as 22 being more important than the charge at the P9 arginine 23 in determining antagonist activity. 24 Subsequent strategies involved the substitution of 26 variant residues in the antagonistic mEGF(33-42) with 27 those present in the agonistic Lam. β -1₍₉₂₅₋₉₃₃₎ sequence 28 (peptides I-III), in an effort to identify key amino 29 acids in the C-terminal regions (P5-10) of the two 30

25

ligands responsible for their contrasting bioactivities.

32 33

31

Substitution of isoleucine (P6) for serine (peptide I) 34 resulted in both reduced receptor affinity and potency 35

PCT/GB99/01211 WO 99/54356 26

in displacement of cell adhesion to laminin. However, 1 this analogue retained weak antagonist activities in

- 2 the motility assay. It is therefore of interest that
- 3 studies on the YIGSR sequence indicate that residue
- 4
- substitution, at the position taken by isoleucine in 5
- the pentapeptide, are well tolerated and may increase 6
- potency (Kawasaki et al 1994). 7

8

- Replacement of aspartate (P8) with serine (peptide II) 9
- resulted in a complete loss of biological function. as 10
- did peptide III encompassing both the former 11
- (isoleucine (P6) for serine) and latter (serine (P8) 12
- for aspartate) substitutions. Since this $mEGF_{(33-42)}$ 13
- analogue sequence (peptide II) encompasses the active 14
- YIGSR amino acid sequence agonist, it is suggested that 15
- this loss of activity may be attributed to the valine 16
- (P2) and isoleucine (P3) residues in the N-terminal 17
- half of $mEGF_{(33-42)}$. Alternatively, addition of a C-18
- terminal cysteine to the YIGSR sequence is known to 19
- reduce potency (Kawasaki et al 1994). Additional 20
- peptides incorporating the valine (P2) and isoleucine 21
- (P3) substitutions are currently under investigation. 22

23

- The determination of the minimum core peptide structure 24
- is ongoing and involves similar characterisation 25
- studies on a number of sequences truncated at the C-26
- terminal. 27

28

- These studies have thus identified an important 29
- antagonist of 67-LR mediated activities in peptide IV. 30
- The sequence, (AcC(Acm)-VIGYSGD-[Cit]-C-(Acm)-NH2.), may 31
- provide an important template for anti-angiogenic drugs 32
- in that it is resistant to cleavage by trypsin-like 33
- proteases and has been identified as being more potent 34
- than mEGF (33-42) in screening procedures. 35

18

WO 99/54356 PCT/GB99/01211 27

1	<u>Adva</u>	ntages					
2							
3	The	advantages of the invention, and the ways in which					
4	disadvantages of previously known arrangements are						
5	over	come include:					
6							
7	1.	Unlike the native 67LR ligand (laminin β -1 _{925.933}),					
8		which is angiogenic in human models, the mEGF_{3342}					
9		derived agents are anti-angiogenic in human					
10		models.					
11							
12	2.	\mathtt{mEGF}_{33-42} has the advantage of inhibiting both					
13		laminin- and EGF-stimulated angiogenesis.					
14							
15	3.	mEGF ₃₃₋₄₂ prevents tumour cell attachment to					
16		basement membranes.					
17		•					

36

}

IV. VON: EPA MUENCHEN 01 :16- 6- 0 : 17:07 : 16-06-2000

01414298331→

+49 89 23994465:# 4 GB 009901211

09/673785

1

422 Rec'd PCT/PTO 2 0 OCT 2000

1	CLAL	<u>na</u>
2		
3	1	A peptide factor derived from amino acid residues 33
4		to 42 of murine epidermal growth factor peptide or a
5		synthetic equivalent thereof wherein the peptide
6		factor is modified to protect it from proteolytic
7		degradation and the peptide binds to laminin
8		receptors wherein the modifications consist of at
9		least one modification chosen from the group
10		comprising; substitution of tyrosine by tyrosine
11		analogues and substitution of arginine by arginine
12		analogues,
13		
14	2	A peptide as claimed in Claim 1 wherein the
15		peptide is further modified by at least one
16		modification chosen from the group comprising
17		capping the N terminal of the peptide, capping
18		the C terminal of the peptide and capping thiol
19		groups of cysteines.
20		
21	3	A peptide as claimed in claims 1 or 2 wherein
22		tyrosine is substituted by Tic-OH.
23		
24	4	A peptide as claimed in claims 1, 2 or 3 wherein
25		arginine is substituted by Citrulline.
26		
27	5	Use of a peptide factor as claimed in any of the
28		preceding claims in the preparation of a medicament,
29		to bind laminin receptors as an antagonist.
30		
31	6	Use of a peptide factor as claimed in any of the
32		preceding claims in the preparation of a medicament
33		to bind laminin receptors as an agonist.
34		
35	7	Use as claimed in claim 6 in the preparation of a

medicament for healing endothelial cell wounding.

42/ 42

Bart that the many was train that the off mery seed find then the first that the

JV. VON: CPA MUENCHEN 01 :16- 6- 0 ; 17:08 : 01414298331→ +49 89 23994465;# 5 16-06-2000

GB 009901211

2

- Use as claimed in claim 8 or 9 for the treatment of I 8
- retinopathy of immaturity. 2



1/1





Fig 1b



Page 1 of 4



Docket No. 41934/23838

Declaration and Power of Attorney For Patent Application

English Language Declaration

As a below named inventor, I hereby declare that:

my residence, post or	nce address and chizens	illp are as stated below liest to my	riairie,
first and joint inventor	inal, first and sole invent (if plural names are liste ght on the invention entit	or (if only one name is listed below ed below) of the subject matter wh led	r) or an original, ich is claimed and for
PEPTIDE FRAGMENTS TARGETS	S OF MURINE EPIDERMA	L GROWTH FACTOR AS LAMININ	RECEPTOR
the specification of wh	hich		
(check one)			
☐ is attached hereto).		
☑ was filed on 21.0	4.99	as United States Application No.	or PCT International
Application Numb	er PCT/GB99/01211		
and was amended	d on 16.06.2000		
		(if applicable)	
I acknowledge the du known to me to be Section 1.56. I hereby claim foreig Section 365(b) of an any PCT International	aty to disclose to the Unimaterial to patentability gn priority benefits underly foreign application(s) at application which design	ndment referred to above. ited States Patent and Trademark as defined in Title 37, Code of er Title 35, United States Code, for patent or inventor's certificate, mated at least one country other to y checking the box, any foreign ap	Federal Regulations, Section 119(a)-(d) or or Section 365(a) of than the United States,
	or PCT International app	lication having a filing date before	
Prior Foreign Applica			Priority Not Claimed
9808407.2	GB	22.04.98	a
(Number)	(Country)	(Day/Month/Year Filed)	·
		/Do. (Manth D/o File d)	
(Number)	(Country)	(Day/Month/Year Filed)	
(Number)	(Country)	(Day/Month/Year Filed)	_
TO-SB-01 (9-95) (Modified)	** T ** ***	P02/REV02 Patent and Trademark C	Office-U.S. DEPARTMENT OF COMME

pplication(s) listed below:		
(Application Serial No.)	(Filing Date)	Contidential
(Application Serial No.)	(Filing Date)	
(Application Serial No.)	(Filing Date)	
ection 365(c) of any PCT Interna sofar as the subject matter of e nited States or PCT Internationa	tional application designating ach of the claims of this ap I application in the manner	any United States application(s), of the United States, listed below and plication is not disclosed in the priorovided by the first paragraph of 3 United States Patent and Trademan
ection 365(c) of any PCT Interna sofar as the subject matter of e nited States or PCT Internationa .S.C. Section 112, I acknowledg iffice all information known to m ection 1.56 which became availat	tional application designating ach of the claims of this ap I application in the manner part e the duty to disclose to the te to be material to patental to between the filing date of	g the United States, listed below and plication is not disclosed in the prid provided by the first paragraph of 3
ection 365(c) of any PCT Internal sofar as the subject matter of emited States or PCT International S.C. Section 112, I acknowledgus all information known to mection 1.56 which became available PCT International filing date of the	tional application designating ach of the claims of this ap I application in the manner particle to the the duty to disclose to the the to be material to patental to be between the filing date of his application:	the United States, listed below and plication is not disclosed in the prior provided by the first paragraph of 3 United States Patent and Trademarish as defined in Title 37, C. F. R. the prior application and the national
ection 365(c) of any PCT International sofar as the subject matter of elinited States or PCT International S.C. Section 112, I acknowledgoffice all information known to mection 1.56 which became available PCT/GB99/01211	tional application designating ach of the claims of this ap I application in the manner to the duty to disclose to the to be material to patentatiole between the filling date of his application: 21.04.99	the United States, listed below and plication is not disclosed in the prior provided by the first paragraph of 3 United States Patent and Trademar bility as defined in Title 37, C. F. R. the prior application and the national PENDING (Status)

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(patented, pending, abandoned)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. (list name and registration number)

UPCHURCH, Gegory E., Reg. No. 28482 KANG, Grant D., Reg. No. 37651 KLOTZER, Daniel S., Reg. No. 42745 LESKO, Paul A., Reg. No. 45364 KIRK, Ahaji J., Reg. No. 46831 SIECKMANN, Gordon F., Reg. No. 28667 MARRAH, Michael T., Reg. No. 40718 DONAHUE III, Dennis JM, Reg. No. 43591 HALDIMAN, Robert C., Reg. No. 45437

CONFIDENTIAL

Send Correspondence to: PAUL A. LESKO

THOMPSON COBURN LLP ONE FIRSTAR PLAZA ST. LOUIS, MO 63101

Direct Telephone Calls to: (name and telephone number)

PAUL A. LESKO, 314-552-6443

Full name of sole or first inventor NELSON, John		
Sole or first inventor's signature	John Mahr	Date 16 / 11 /0-0
Residence BELFAST, IRELAND	NIR	
Citizenship IE		
Post Office Address 59 ASHLEY AVENUE		
BELFAST BT9 7BU IREL	AND	

ſ	Full name of second inventor, if any WALKER, Brian	
6	Second inventor's signature	15 ^{34!} n) 2000
	Residence DUNDRUM, IRELAND NIR	
	Citizenship IE	
	Post Office Address 10 CASTLEVIEW	
	DUNDRUM BT33 0AS IRELAND	

Form PTO-SB-01 (6-95) (Modified)

Patent and Trademark Office-U.S. DEPARTMENT OF COMME

Full name of third inventor, if any McFERRAN, Neil	CONFIDENTIAL
SPL-12 Language and the second	Date 15 th Neo 200
Residence BELFAST, IRELAND	7.00000
Citizenship IE	
Post Office Address 65 MARLBOROUGH PARK SOUTH	
BELFAST BT9 6HS IRELAND	
Full name of fourth inventor, if any HARRIOTT, Patrick	
Fourth inventor's signature 7. Hamil	16-11-5000 16-11-5000
Residence BELFAST, IRELAND NIR	
Citizenship IE	
Post Office Address 12 WILLIAM ALEX PARK, FINAGHY	
BELFAST BT10 OLN IRELAND	
Full name of fifth inventor, if any	
Fifth inventor's signature	Date
Residence	
Citizenship	
Post Office Address	
Full name of sixth inventor, if any	
Sixth Inventor's signature	Date
Residence	
Citizenship	
Post Office Address	

Form PTO-SB-01 (6-95) (Modified)

Patent and Trademark Office-U.S. DEPARTMENT OF COMMERCE